Publications database

This meeting report provides an overview of the content of the DRID meeting that took place online on 22-23 October 2020, focusing on: the direct and indirect impact of COVID-19 on drug...

In this update from the the EU Early Warning System aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning...

This document describes the EMCDDA's Reitox certification process. The Reitox certification project is a process for formal acknowledgement of the competence of an EMCDDA national focal point to carry out specific tasks...

The Evidence database is a core component of the EMCDDA’s Best Practice Portal. The portal is a resource for professionals, policymakers and researchers in the drugs field and provides information on the...

This report highlights the responses taken by the EMCDDA's Reitox network of national focal points to the COVID-19 crisis and describes the challenges met by the organisations and the strategies produced to...

This paper provides an analysis of the available data that suggest that a methamphetamine industry is rapidly being established in Afghanistan. The analysis provided is based on information from key informants, documentary...

This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020. On the basis...

This report presents the results of the seventh ESPAD data-collection wave, conducted in 35 countries during the spring and autumn of 2019. It paints a comprehensive picture of the present situation among...

Methyl 2-({[1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl}amino)-3,3-dimethylbutanoate (4F-MDMB-BICA) is a synthetic cannabinoid receptor agonist. Similar to other synthetic cannabinoids, it is sold as a ‘legal’ replacement for cannabis. Because of their high potency, synthetic cannabinoids can pose...

Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA) is a synthetic cannabinoid receptor agonist. Similar to other synthetic cannabinoids, it is sold as a ‘legal’ replacement for cannabis and controlled synthetic cannabinoids. Because of their high potency...